A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia.

Abstract:

:In order to determine the efficacy of the antifibrinolytic agent tranexamic acid (TA) in reducing bleeding and platelet transfusions during the treatment of acute myeloid leukemia (AML), we conducted a randomized placebo-controlled double-blind study. Patients with AML undergoing induction or postremission consolidation chemotherapy were randomized into TA or placebo groups. Patients were not given platelet transfusions prophylactically but only when bleeding occurred. The severity of any bleeding event was scored. Thirty eight patients were randomized during induction. There were no significant differences between the two groups in the number of bleeding events and their severity or in the number of platelet transfusions given. Eighteen patients were studied during consolidation. In contrast, to the induction period, during consolidation there was a significantly less severe bleeding tendency in the TA group resulting in a lower platelet transfusion requirement [3.7 +/- 4.1 vs. 9.3 +/- 3.3 platelet units (p < .05)]. TA was well tolerated and no side effects were seen and no specific thromboembolic events were noticed. We conclude that giving TA during the thrombocytopenic period of AML patients undergoing consolidation chemotherapy is beneficial and safely reduces platelet transfusions.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Shpilberg O,Blumenthal R,Sofer O,Katz Y,Chetrit A,Ramot B,Eldor A,Ben-Bassat I

doi

10.3109/10428199509059668

subject

Has Abstract

pub_date

1995-09-01 00:00:00

pages

141-4

issue

1-2

eissn

1042-8194

issn

1029-2403

journal_volume

19

pub_type

临床试验,杂志文章,随机对照试验
  • Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.

    abstract::Preclinical studies suggest that bortezomib, through inhibition of nuclear factor-κB (NF-κB) activation, may enhance the effects of radioimmunotherapy. This phase I trial was designed to determine the maximum tolerated dose (MTD) of weekly bortezomib induction combined with Y-90-ibritumomab tiuxetan followed at the ti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.722215

    authors: Roy R,Evens AM,Patton D,Gallot L,Larson A,Rademaker A,Cilley J,Spies S,Variakojis D,Gordon LI,Winter JN

    更新日期:2013-03-01 00:00:00

  • Expression of CD203c on basophils as a marker of immunoglobulin E-mediated (L)-asparaginase allergy.

    abstract::Immediate allergy to l-asparaginase (ASP) is a major obstacle in treating lymphoid malignancies. ASP-specific immunoglobulin G (ASP-IgG) has been used as a surrogate marker. Recently, the CD203c-basophil activation test (BAT) was found to be useful in diagnosing IgE-mediated allergies. We compared the diagnostic utili...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.794944

    authors: Hino M,Shimojo N,Ochiai H,Inoue Y,Ando K,Chikaraishi K,Ota S,Okimoto Y,Sunami S,Nakamura R,Teshima R,Sato Y,Kohno Y

    更新日期:2014-01-01 00:00:00

  • Expression of HOX genes in acute leukemia cell lines with and without MLL translocations.

    abstract::In primary cells from acute leukemia patients, expression of the genes MEIS1, HOXA5, HOXA7 and HOXA9 has been reported to be correlated with the occurrence of MLL translocations. It was our aim to find out whether MLL mutant (MLLmu) and MLL wild-type (MLLwt) acute leukemia-derived cell lines might likewise be discrimi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001609942

    authors: Quentmeier H,Dirks WG,Macleod RA,Reinhardt J,Zaborski M,Drexler HG

    更新日期:2004-03-01 00:00:00

  • cAMP/PKA-mediated regulation of erythropoiesis.

    abstract::The role of cyclic AMP (cAMP) as second messenger in erythropoiesis has been suggested in the early 1980s. However, careful analysis showed that cAMP is not generated in direct response to the main erythropoiesis-controlling cytokines such as erythropoietin (Epo). As a result, cAMP disappeared from the central stage i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000116715

    authors: Boer AK,Drayer AL,Vellenga E

    更新日期:2003-11-01 00:00:00

  • Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.

    abstract::The immune cell composition of the follicular lymphoma (FL) tumor microenvironment is increasingly recognized as an important determinant for clinical outcome. Here, we explored frequency and distribution of dendritic cell (DC) subtypes in relation to regulatory T cells (Treg) by immunohistochemistry in lymph node bio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1135432

    authors: Chevalier N,Mueller M,Mougiakakos D,Ihorst G,Marks R,Schmitt-Graeff A,Veelken H

    更新日期:2016-09-01 00:00:00

  • Non-Hodgkin's lymphoma presenting as anasarca: probably mediated by tumor necrosis factor alpha (TNF-alpha).

    abstract::Two patients presented with anasarca, fevers and sweats. Subsequent evaluation revealed aggressive lymphoproliferative disease. Both patients were treated with CHOP chemotherapy. One patient responded with spontaneous, vigorous diuresis and complete resolution of the edema. She relapsed two months later with recurrent...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009087034

    authors: Jillella AP,Day DS,Severson K,Kallab AM,Burgess R

    更新日期:2000-07-01 00:00:00

  • Nuclear Topoisomerase II Activity Changes During HL-60 Leukemic Cell Differentiation: Alterations in Drug Sensitivity and pH Dependency.

    abstract::We have studied the effect of dimethyl-sulfoxide(DMSO)-induced granulocytic differentiation on the sensitivity of HL-60 cells to various cytotoxic topoisomerase II inhibitors: (i) undifferentiated HL-60 cells are highly sensitive to etoposide, while differentiated HL-60 cells are 700-1000 fold resistant to etoposide, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068137

    authors: Gieseler F,Boege F,Biersack H,Spohn B,Clark M,Wilms K

    更新日期:1991-01-01 00:00:00

  • Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.

    abstract::Next-generation sequencing (NGS) is increasingly employed for diagnosis, risk stratification, and management of patients with myelodysplastic syndrome (MDS). We aimed to describe beliefs and practice patterns among providers who treat MDS patients with respect to the utility of NGS in diagnosis, risk stratification, p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1723013

    authors: Pine AB,Chokr N,Stahl M,Steensma DP,Sekeres MA,Litzow MR,Luger SM,Stone RM,Greenberg PL,Bejar R,Bewersdorf JP,Gore SD,Zeidan AM

    更新日期:2020-06-01 00:00:00

  • Tocilizumab, in search for a role in acute GVHD.

    abstract::Acute graft versus host disease (aGVHD) was first described by Barnes et al. in 1962, who reported a 'secondary disease' in mice after irradiation and infusion of allogeneic spleen cells. The disease manifested as fatal diarrhea and skin abnormalities. They postulated that aGVHD resulted from introducing immunological...

    journal_title:Leukemia & lymphoma

    pub_type: 评论,杂志文章

    doi:10.1080/10428194.2019.1613545

    authors: Gergis U,van Besien K

    更新日期:2019-09-01 00:00:00

  • Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.

    abstract::The long-term results of postremission chemotherapy for 122 consecutive, unselected adults (15-65 years) with acute myeloid leukemia (AML) were assessed in two sequential prospective studies involving an identical 3/7-type induction regimen, and in those achieving remission, another course for early consolidation usin...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428199409051684

    authors: Jehn U

    更新日期:1994-09-01 00:00:00

  • Primary myeloid sarcoma of the gynecologic tract: a report of two cases progressing to acute myeloid leukemia.

    abstract::Primary gynecologic myeloid sarcomas are rare, and their diagnosis is often difficult. Differential diagnosis includes lymphomas and carcinomas of the gynecologic tract. We report the clinical, morphological, immunohistochemical and cytogenetic features of two cases of chloromas of the female genital tract, which prog...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000016096

    authors: Hernández JA,Navarro JT,Rozman M,Ribera JM,Rovira M,Bosch MA,Fantova MJ,Mate JL,Millá F

    更新日期:2002-11-01 00:00:00

  • Childhood acute lymphoblastic leukemia: is there a tumor suppressor gene in chromosome 12p12.3?

    abstract::Cytogenetic deletions on the short arm of chromosome 12 are common, recurring alterations found in a wide range of hematological neoplasias, including childhood acute lymphoblastic leukemia (ALL), the most frequent pediatric malignancy. This loss of genetic material suggests the presence of a tumor suppressor gene pla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909050948

    authors: Aïssani B,Bonan C,Baccichet A,Sinnett D

    更新日期:1999-07-01 00:00:00

  • The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.

    abstract::Abstract ATM gene alteration is a frequent event in pathogenesis of chronic lymphocytic leukemia (CLL) and occurs as monoallelic loss in the form of 11q23 deletion, with and without mutation in the remaining ATM allele. ATM is a principal DNA damage response gene and biallelic ATM alterations lead to ATM functional lo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.829919

    authors: Stankovic T,Skowronska A

    更新日期:2014-06-01 00:00:00

  • The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.

    abstract::Several studies have indicated that age, hemoglobin and serum albumin are among the most important prognostic factors for survival of patients with Waldenstrom's macroglobulinemia (WM). Furthermore, recent data indicate that serum b2-microglobulin may be also significant. The recently proposed International Staging Sy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001687512

    authors: Dimopoulos M,Gika D,Zervas K,Kyrtsonis M,Symeonidis A,Anagnostopoulos A,Bourantas K,Matsouka C,Pangalis G

    更新日期:2004-09-01 00:00:00

  • Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.

    abstract::The overall cure rate of adults with newly-diagnosed acute myelogenous leukemia (AML) treated with continuous infusion high-dose cytarabine (CIHDAC) is comparable to that with standard-dose ara-C plus anthracycline or amsacrine (AMSA). We tested whether the addition of AMSA to CIH-DAC improves the outcome of adults wi...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199609051730

    authors: Ghaddar HM,Pierce S,Kantarjian HM,Freireich EJ,Keating MJ,Estey EH

    更新日期:1996-06-01 00:00:00

  • Initial therapy for acute myeloid leukemia in older patients: principles of care.

    abstract::Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1323275

    authors: Bhatt VR,Gundabolu K,Koll T,Maness LJ

    更新日期:2018-01-01 00:00:00

  • Coexistent multiple myeloma and myelofibrosis.

    abstract::Although the association of bone marrow fibrosis with plasma cell dyscrasias has already been described in several reports, the close relationship between these entities still remains unclear. In this report we describe a patient with clinical and pathologic findings which initially suggested a diagnosis of myelofibro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309148567

    authors: Pulsoni A,Bianco P,La Verde G,Mecarocci S,Petrucci MT,Torromeo C,Avvisati G

    更新日期:1993-07-01 00:00:00

  • Molecular analysis of infant acute leukemia.

    abstract::Infant acute leukemia, known to have a poor outcome with conventional therapy, usually has a molecular rearrangement at chromosome band 11q23. The 11q23 translocation partner is typically at 4q21 in infant ALL, but other 11q23 translocation partners occur in infant ALL and AML. The MLL gene at 11q23, and the AF4 gene ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709114159

    authors: Hilden JM,Frestedt JL,Kersey JH

    更新日期:1997-04-01 00:00:00

  • Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.

    abstract::Immune suppression is a hallmark of multiple myeloma (MM), but data on soluble factors involved in the fate of immune effector cells are limited. The CXCR3-binding chemokine monokine induced by interferon-gamma (MIG/CXCL9) has been associated with tumor progression, immune escape, and angiogenesis in several malignanc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2016.1151511

    authors: Bolomsky A,Schreder M,Hübl W,Zojer N,Hilbe W,Ludwig H

    更新日期:2016-11-01 00:00:00

  • Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.

    abstract::The aim of the study was efficacy and toxicity evaluation of combination of 2-Chlorodeoxyadenosine (2-CdA) with cytarabine (Ara-C) and G-CSF (CLAG regimen) as reinduction therapy in patients with refractory or relapsed acute myeloid leukemia (AML). The protocol stipulated an infusion of 5 mg/m2 of 2-CdA over 2 hours d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009053545

    authors: Robak T,Wrzesień-Kuś A,Lech-Marańda E,Kowal M,Dmoszyńska A

    更新日期:2000-09-01 00:00:00

  • Acute myelogenous leukemia complicated by acute necrotizing ulcerative gingivitis due to Aspergillus terreus.

    abstract::Infections caused by Aspergillus terreus are rare but have been associated with a poor outcome in immunocompromised patients due to frequent resistance to conventional antifungal therapy. This report describes a case of a woman who developed acute necrotizing ulcerative gingivitis (ANUG) due to A. terreus during induc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000060573

    authors: Khoury H,Poh CF,Williams M,Lavoie JC,Nevill TJ

    更新日期:2003-04-01 00:00:00

  • Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity.

    abstract::Myeloablative doses of busulfan (Bu) with fludarabine (Flu) have reduced toxicity, however, limited by an increased relapse rate. We aimed to improve outcome of Flu-Bu regimen by augmentation with thiotepa (TT) (10 mg/kg). Eighty-nine patients with AML, 44 patients conditioned with Flu-Bu (group 1), and 45 patients au...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1510495

    authors: Sheth V,Nachmias B,Grisariu S,Avni B,Or R,Shapira M

    更新日期:2019-03-01 00:00:00

  • Invasive fungal sinusitis: an effective combined treatment in five haematological patients.

    abstract::Invasive fungal rhinosinusitis (IFR) is a life-threatening infection. Its onset is subtle and a late diagnosis leads to severe complications. Death may occur within a few weeks notwithstanding treatment. We describe a comprehensive pre- and post-operative approach to care for haematological patients with IFR. Five hae...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701457923

    authors: Vener C,Carrabba M,Fracchiolla NS,Costa A,Fabio G,Hu C,Sina C,Guastella C,Pignataro L,Deliliers GL

    更新日期:2007-08-01 00:00:00

  • Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.

    abstract::Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.627480

    authors: Nicolini FE,Masszi T,Shen Z,Gallagher NJ,Jootar S,Powell BL,Dorlhiac-Llacer PE,Zheng M,Szczudlo T,Turkina A

    更新日期:2012-05-01 00:00:00

  • Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies.

    abstract::Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammop...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509054750

    authors: Vacca A,Ribatti D,Roncali L,Dammacco F

    更新日期:1995-12-01 00:00:00

  • Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma.

    abstract::Peripheral blood progenitor cells are being used increasingly as part of the treatment protocol for a variety of haematological malignancies. The most appropriate mobilisation therapy and the optimum collection procedures have yet to be fully elucidated. 28 patients with myeloma (9), NHL (11) and HD (8) underwent PBSC...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509112208

    authors: Scott MA,Ager S,Apperley JF,Jestice HK,Bloxham DM,Boraks P,Mahendra P,Marcus RE

    更新日期:1995-11-01 00:00:00

  • Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia.

    abstract::We prospectively examined the frequency of the t(12;21)TEL-AML1 fusion in 504 children with newly diagnosed standard risk ALL using RT-PCR assays. Cells from 95 patients (18.8%) were TEL-AML1+. There was a significantly higher frequency of pseudodiploidy among the TEL-AML1+ cases (39.4% versus 14.1%, P = 0.001), prima...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097675

    authors: Uckun FM,Pallisgaard N,Hokland P,Navara C,Narla R,Gaynon PS,Sather H,Heerema N

    更新日期:2001-06-01 00:00:00

  • Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

    abstract::Hematologic malignancies are predominantly treated with chemotherapy or a combination of chemotherapy with monoclonal antibodies. Current treatment regimens often are not satisfactory due to severe side effects and a substantial proportion of relapsed patients. This has prompted the development of better tolerated and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190902943077

    authors: Nagorsen D,Bargou R,Ruttinger D,Kufer P,Baeuerle PA,Zugmaier G

    更新日期:2009-06-01 00:00:00

  • Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.

    abstract::High-dose melphalan therapy with peripheral blood stem cell (PBSC) transplantation is a standard treatment for younger patients with untreated multiple myeloma that results in high overall and complete response (CR) rates, and improved event-free and overall survival compared with standard chemotherapy alone. Inductio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190701540991

    authors: Oakervee H,Popat R,Cavenagh JD

    更新日期:2007-10-01 00:00:00

  • Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.

    abstract::Bryostatin, a macrocyclic lactone and protein kinase C (PKC) modulator, has been shown to have differentiation and anti-tumor activity against several leukemia cell lines in vitro. In this study, we demonstrated Bryostatin-induced differentiation in B-cell chronic lymphocytic leukemia (B-CLL) cells, characterized by a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001639470

    authors: Thomas A,Pepper C,Hoy T,Bentley P

    更新日期:2004-05-01 00:00:00